Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes

Cardiovasc Diabetol. 2013 Jun 27:12:97. doi: 10.1186/1475-2840-12-97.

Abstract

Background: It has been reported that hyperglycemia following hypoglycemia produces an ischemia-reperfusion-like effect in type 1 diabetes. In this study the possibility that GLP-1 has a protective effect on this phenomenon has been tested.

Methods: 15 type 1 diabetic patients underwent to five experiments: a period of two hours of hypoglycemia followed by two hours of normo-glycemia or hyperglycemia with the concomitant infusion of GLP-1 or vitamin C or both. At baseline, after 2 and 4 hours, glycemia, plasma nitrotyrosine, plasma 8-iso prostaglandin F2alpha, sCAM-1a, IL-6 and flow mediated vasodilation were measured.

Results: After 2 h of hypoglycemia, flow mediated vasodilation significantly decreased, while sICAM-1, 8-iso-PGF2a, nitrotyrosine and IL-6 significantly increased. While recovering with normoglycemia was accompanied by a significant improvement of endothelial dysfunction, oxidative stress and inflammation, a period of hyperglycemia after hypoglycemia worsens all these parameters. These effects were counterbalanced by GLP-1 and better by vitamin C, while the simultaneous infusion of both almost completely abolished the effect of hyperglycemia post hypoglycemia.

Conclusions: This study shows that GLP-1 infusion, during induced hyperglycemia post hypoglycemia, reduces the generation of oxidative stress and inflammation, improving the endothelial dysfunction, in type 1 diabetes. Furthermore, the data support that vitamin C and GLP-1 may have an additive protective effect in such condition.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antioxidants / administration & dosage*
  • Ascorbic Acid / administration & dosage*
  • Biomarkers / blood
  • Blood Glucose / drug effects*
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / diagnosis
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / physiopathology
  • Dinoprost / analogs & derivatives
  • Dinoprost / blood
  • Female
  • Glucagon-Like Peptide 1 / administration & dosage*
  • Humans
  • Hyperglycemia / blood
  • Hyperglycemia / diagnosis
  • Hyperglycemia / drug therapy*
  • Hyperglycemia / physiopathology
  • Hypoglycemia / blood
  • Hypoglycemia / diagnosis
  • Hypoglycemia / drug therapy*
  • Hypoglycemia / physiopathology
  • Hypoglycemic Agents / administration & dosage*
  • Inflammation / blood
  • Inflammation / prevention & control
  • Inflammation Mediators / blood
  • Infusions, Parenteral
  • Intercellular Adhesion Molecule-1 / blood
  • Interleukin-6 / blood
  • Male
  • Oxidative Stress / drug effects
  • Reperfusion Injury / blood
  • Reperfusion Injury / diagnosis
  • Reperfusion Injury / physiopathology
  • Reperfusion Injury / prevention & control*
  • Time Factors
  • Treatment Outcome
  • Tyrosine / analogs & derivatives
  • Tyrosine / blood
  • Vasodilation / drug effects
  • Young Adult

Substances

  • Antioxidants
  • Biomarkers
  • Blood Glucose
  • Hypoglycemic Agents
  • ICAM1 protein, human
  • IL6 protein, human
  • Inflammation Mediators
  • Interleukin-6
  • Intercellular Adhesion Molecule-1
  • 8-epi-prostaglandin F2alpha
  • 3-nitrotyrosine
  • Tyrosine
  • Glucagon-Like Peptide 1
  • Dinoprost
  • Ascorbic Acid